{"entity":{"id":"nct05427383","kind":"trial","name":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","aka":[],"tldr":"A phase 2/3 trial of Docetaxel in gastric & gastro-oesophageal junction cancer, run by Shanghai JMT-Bio Inc., now recruiting.","summary":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy is a phase 2/3 interventional study registered as NCT05427383 by Shanghai JMT-Bio Inc., with 286 participants planned, started 2022-04-07 and due to reach its primary completion in 2025-11. Interventions recorded: KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection and Irinotecan Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05427383","url":"https://clinicaltrials.gov/study/NCT05427383"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["docetaxel"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05427383","phase":"2/3","setting":"A Randomized, Multicenter, Phase Ⅱ/Ш Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy.","sponsor":"Shanghai JMT-Bio Inc.","enrolled":286,"outcomes":[]},"route":"/trials/nct05427383/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}